FDAnews Drug Daily Bulletin

FORTEBIO RAISES $17.3 MILLION IN SERIES B FINANCING

Nov. 1, 2005
A A

ForteBio, Inc., a life sciences company providing tools for the detection and analysis of biomolecules and their interactions, today announced the close of a $17.3 million Series B Preferred Stock financing. The round was led by The Vertical Group, a New Jersey-based venture capital firm that is focused on the fields of medical technology and biotechnology. All of the company's existing investors, Agilent Ventures, Alloy Ventures, Latterell Venture Partners, and Versant Ventures, participated in this financing.

Yahoo News (http://biz.yahoo.com/prnews/051026/sfw047.html?.v=35)